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Background: Xingnaojing injection (XNJ) is the only Chinese herbal injection approved for
both intracerebral hemorrhage and ischemic stroke (IS) first-aid on ambulances in China;
many systematic reviews (SRs) and meta-analyses (MAs) of XNJ on stroke have been
published. The purpose of this research was to evaluate and summarize the current
evidence on XNJ for IS.
Methods: A comprehensive search was conducted for SRs and MAs of XNJ on IS in
seven databases up to January 1, 2021. Two authors independently identified SRs and
MAs, extracted data, assessed the quality of the included SRs and MAs using the
Assessment of Multiple Systematic Reviews 2 (AMSTAR 2), and assessed quality of
evidence using the Grading of Recommendations, Assessment, Development, and
Evaluation (GRADE).
Results: A total of 10 SRs met the inclusion criteria. The quality of included SRs using
AMSTAR 2 was critically low as the critical items were poorly reported. Only 10% of SRs
reported 50% of the 16 items, while the remaining 90% SRs reported just less than half of
the items on AMSTAR 2. For GRADE, 7 (35%) of outcomes had low-quality evidence, 10
(50%) with very low, and 3 (15%) with moderate quality evidence. Very low to low quality of
evidence indicated XNJ plus conventional therapy (CT) alleviated the neurological deficits
of acute IS. Moderate-quality evidence showed XNJ plus CT reduced mortality when
compared to Danshen injection plus CT, and very low-quality evidence showed XNJ plus
CT could not improve the degree of coma, while low-quality evidence indicated the
opposite. Mild adverse events in the CT group were less than those in the XNJ plus CT
group, and there were no serious adverse events, but there was no statistical difference
between the two groups. The included 10 SRs indicated that XNJ was used for acute IS,
but only four SRs (40%) reported the course of disease.
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Conclusion: XNJ appears to be effective and safe for acute IS in improving the
neurological deficits, but the evidence is not robust enough. However, whether
administering XNJ immediately after or within 24 h of IS is best remains unknown due
to the lack of data. Well-designed large-scale randomized controlled trials with measurable
outcomes are required in future studies.
Keywords: Chinese herbal medicine, Xingnaojing injection, acute ischemic stroke, overview, systematic reviews,
meta-analyses
INTRODUCTION
As the second leading cause of deaths worldwide, stroke is also
problematic because it results in high morbidity, disability, and
recurrence (GBD 2016 Stroke Collaborators, 2019; GBD 2016
Causes of Death Collaborators, 2017). In addition, there is a large
economic burden due to the various life-influencing handicaps
experienced by stroke survivors who need extensive and
individual treatment and healthcare (Rajsic et al., 2019).
Ischemic stroke (IS) is the main subtype of stroke with the
proportion more than 80% (Benjamin et al., 2019).
Vascular recanalization strategies including intravenous
thrombolysis and endovascular treatment are recommended to
timely accelerate reperfusion (Powers et al., 2019). Unfortunately,
although substantial advances in treatment at the acute stage of IS
have emerged in recent years, only a minority of patients can
clinically benefit from vascular recanalization treatment (Liu
et al., 2011; Demaerschalk et al., 2016). The unavoidable
reasons for this strict time-window restrictions include,
increased risk of hemorrhagic transformation, imaging
dependence and technical surgical operation requirement
(Yaghi et al., 2017; Powers et al., 2019). It will be hard to
reverse the functional status of IS survivors once they miss the
crucial 24 h immediately after stroke onset. There are many
potential neuroprotective agents that can be explored, but
randomized controlled trials (RCTs) are required to prove
their effectiveness.
Xingnaojing injection (XNJ) is one of the China Food and
Drug Administration’s approved neuroprotective agents for the
treatment of acute stroke, and it is widely used in China (Wu
et al., 2007). It is the only Chinese herbal injection approved for
both intracerebral hemorrhage and ischemic stroke as a first-aid
option on ambulances in China, but whether initiating treatment
of XNJ for acute IS immediately after onset remains unknown.
XNJ is extracted from a classical, well-known Chinese patent
medicine that has been used clinically for more than 200 years.
XNJ contains Moschus, Borneolum syntheticum, Gardenia
jasminoides J.Ellis, and Curcuma aromatica Salisb. as well as
appropriate amount of other ingredients. The theory of
traditional Chinese medicine (TCM) believes that stroke is
caused by phlegm-fire and other pathogenic factors that can
affect the mind, reverse qi and blood, and result in blood stasis
and block in the brain. Moschus can awake the brain and activate
blood circulation, borneolum can also awake the brain and clear
heat, while Gardenia has the effect of clearing heat and
detoxification, and the Curcuma has the effect of promoting qi
and blood circulation, so the ingredients together have the
function of clearing heat and detoxification, cooling and
activating blood circulation, and awakening the brain (Chinese
Pharmacopoeia Commission, 2020). Basic research has shown
the benefits of XNJ in treating IS, suggesting that XNJ is effective
in alleviating inflammatory reactions, such as lowering TNF-a,
IL-6, and IL-1b, in addition to improving the body’s antioxidant
function (Ma et al., 2018). It is generally recognized that
systematic reviews and meta-analyses are the cornerstones of
evidence-based health care (Pieper et al., 2014), and such SRs on
the use of XNJ for IS had been published. Previous systematic
reviews (SRs) and meta-analyses (MAs) indicated that there was
insufficient evidence to confirm the efficacy and safety of XNJ in
treating IS (Li, 2006). The latest systematic review and meta-
analyses suggested that there was significant benefit of XNJ in
alleviating neurological impairment (Ma et al., 2017). In addition
to the conflicts existing between different SRs and MAs, the exact
time-window for initiating XNJ and duration of XNJ use for IS
treatment were not documented in some studies (Li, 2006; Ma
et al., 2013). Moreover, the primary outcomes of these studies
were either a composite endpoint (cure rate, obvious effective
rate, and effective rate) or the improvement of neurological
impairment, which lacks robust support strength. As SRs and
MAs with low quality may mislead clinical decision-making, a
systematic overview that evaluates all systematic reviews can
identify the quality of the methodology and the evidence from
important outcomes using the GRADE approach. It has been
acknowledged that overviews are valuable for clinical decision-
making as they avoid uncertainty caused by conflicting
conclusions from different reviews, and facilitate the discovery
of potential evidence gaps (Smith et al., 2011; Yang et al., 2017).
As the current evidence from different SRs andMAs about XNJ in
treating IS has not previously been assessed systematically, we
conducted this overview of systematic reviews to provide an
overall evaluation of the quality of evidence and summarize
the current evidence about XNJ for the treatment of IS.
METHODS
This overview was performed based on a predefined protocol
drafted according to the Cochrane Handbook for conducting
overviews of SRs and MAs of interventions (Higgins Jpt, 2019).
Inclusion and Exclusion Criteria
Type of study: As RCTs are considered to provide high-quality
evidence for assessing interventions, we included SRs of RCTs or
quasi-RCTs assessing the effectiveness and safety of XNJ for IS.
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Type of subjects: Subjects included had to be diagnosed as IS;
there were no limitations on age, race, and gender.
Type of intervention: XNJ was used alone or combined with
other therapies (like placebo, rehabilitation training, conventional
therapy (CT, including thrombolysis, restoring blood supply to
ischemic area, controlling cerebral edema, controlling
hypertension, and reducing blood viscosity), and western
medicine such as cerebral protection agents) in the treatment
groups. The comparator interventions were CT, western
medicine, placebo, rehabilitation training, or other herbal
injection.
Type of outcome measures: Any effect-related outcomes were
measured, such as mortality, disability, neurological deficit score,
and adverse reactions, using activity of daily living assessment
(like Barthel Index) and Glasgow Coma Scale (GCS).
Any duplicate publications were excluded. Conference
abstracts were excluded if the relevant data were not supplied.
Search Strategy
Seven electronic databases were searched without language
limitation (from their inception to February 20, 2020). These
included PubMed, EMBASE, Cochrane library, China
National Knowledge Infrastructure (CNKI), China Science
Technology Journal Database (VIP), Wanfang Database,
and Sino-Med Database. We updated the search until
January 1, 2021, before submission and included the latest
published SRs and MAs that met the inclusion criteria. The
searching strategies on PubMed and CNKI are listed in
appendix 1 (Appendix 1).
Study Selection and Data Extraction
Two reviewers (CYZ and DHX) independently identified SRs and
MAs according to the predefined eligibility criteria and then
independently extracted the basic information of the final
included SRs and MAs according to the predesigned
extraction table. Any disagreements were resolved by
discussion or consultation with a third reviewer (YX). The
basic information of SRs and MAs extracted were as follows:
initials of the first author, publication year, number of included
RCTs or q-RCTs, sample size, course and severity of IS,
interventions in treatment and control groups, adverse events,
outcomes, and main conclusions of included SRs and MAs.
Quality Assessment
Methodological Quality by Assessment of Multiple
Systematic Reviews 2
Two reviewers (CYZ and DHX) separately assessed the quality of
included SRs and MAs using the Assessment of Multiple
Systematic Reviews 2 (AMSTAR2) (Shea et al., 2017). Each of
the 16 items was rated as “yes” (if the item was answered
completely), “no” (the item was absent or not appropriate), or
“partial yes” (some of the subitems incomplete). An overall rating
(high, moderate, low, and critically low) was evaluated as follows:
overall quality was assessed as high when there was no or just one
noncritical weakness (item 2, item 4, item 7, item 9, item 11, item
13, and item 15 as critical items; others as noncritical items);
moderate when there was just more than one noncritical
weakness; low when there was just one critical flaw; and
critically low when there was more than one critical flaw. Any
discrepancies in the 16 items were resolved by discussion or
judged by a third author (YX).
Evidence Quality by Grading of
Recommendations, Assessment,
Development, and Evaluation
The Grading of Recommendation, Assessment, Development,
and Evaluation (GRADE) system was used to assess the quality of
the key outcomes (Guyatt et al., 2011). Two reviewers (YX and
RRA) separately assessed the quality of the included SRs andMAs
with GRADE; any discrepancies were resolved by discussion or
judged by a third author (ZYT).
Five rating down factors were as follows: risk of bias,
inconsistencies, indirectness, inaccuracy, and publication bias
(Guyatt et al., 2008).
RESULTS
Study Selection
A total of 235 articles were identified from seven databases.
After 114 duplications were removed, we reviewed 121
records by title and abstract. And 31 were reviewed by full
text. There were no SRs and MAs included after update
retrieval. Finally, 10 studies meeting the inclusion criteria
were included in our study (Xu et al., 2005; Li, 2006; Wang
et al., 2006; Lin et al., 2010; Li et al., 2013; Ma et al., 2013;
Chen and Gu, 2017; Ma et al., 2017; Wang et al., 2017; Liao
et al., 2019).
The study flowchart is shown in Figure 1.
Characteristics of Systematic Reviews
The characteristics of the included SRs and MAs are summarized
in Table 1. A total of 10 studies were identified dating between
2006 and 2019 (Xu et al., 2005; Li, 2006; Wang et al., 2006; Lin
et al., 2010; Li et al., 2013; Ma et al., 2013; Chen and Gu, 2017; Ma
et al., 2017; Wang et al., 2017; Liao et al., 2019): only 1 SR was
published in an English-language journal (Ma et al., 2017), and
another nine were in Chinese-language journals (Xu et al., 2005;
Li, 2006;Wang et al., 2006; Lin et al., 2010; Li et al., 2013;Ma et al.,
2013; Chen and Gu, 2017;Wang et al., 2017; Liao et al., 2019). The
first authors and the corresponding authors of the 10 SRs were
from China (Xu et al., 2005; Li, 2006; Wang et al., 2006; Lin et al.,
2010; Li et al., 2013; Ma et al., 2013; Chen and Gu, 2017; Ma et al.,
2017; Wang et al., 2017; Liao et al., 2019). As for the included
study type, 1 SR included RCTs or quasi-RCTs (Wang et al.,
2006), and 9 SRs only included RCTs (Xu et al., 2005; Li, 2006; Lin
et al., 2010; Li et al., 2013; Ma et al., 2013; Chen and Gu, 2017; Ma
et al., 2017; Wang et al., 2017; Liao et al., 2019). The primary
studies included in each SR ranged from 3 to 53, and the number
of patients varied from 160 to 4,915. XNJ was used for acute IS in
all SRs (Xu et al., 2005; Li, 2006; Wang et al., 2006; Lin et al., 2010;
Li et al., 2013; Ma et al., 2013; Chen and Gu, 2017; Ma et al., 2017;
Wang et al., 2017; Liao et al., 2019), and administration of XNJ in
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the patients with acute stroke was within 14 days from stroke
onset in 2 SRs (Wang et al., 2006; Wang et al., 2017), within
30 days in 2 SRs (Li, 2006;Ma et al., 2013), and was unclear for the
remaining 6 SRs (Xu et al., 2005; Lin et al., 2010; Li et al., 2013;
Chen and Gu, 2017; Ma et al., 2017; Liao et al., 2019). All included
SRs did not mention the severity of acute IS (Xu et al., 2005; Li,
2006; Wang et al., 2006; Lin et al., 2010; Li et al., 2013; Ma et al.,
2013; Chen and Gu, 2017; Ma et al., 2017; Wang et al., 2017; Liao
et al., 2019). As for the types of intervention, XNJ was used as an
additive therapy, and the treatment in the intervention group was
XNJ plus CT (Xu et al., 2005; Li, 2006;Wang et al., 2006; Lin et al.,
2010; Li et al., 2013; Ma et al., 2013; Chen and Gu, 2017; Ma et al.,
2017; Wang et al., 2017; Liao et al., 2019). While in the control
group, the treatment in 6 SRs were CT (Lin et al., 2010; Li et al.,
2013; Chen and Gu, 2017; Ma et al., 2017; Wang et al., 2017; Liao
et al., 2019), 2 SRs were CT plus other therapy (Xu et al., 2005; Li,
2006), 1 was CT or CT plus other therapy (Wang et al., 2006), and
there was no limitation on treatment in the control group in 1 SR
(Ma et al., 2013). All the included SRs concluded that there was
very low to low-quality evidence on the effectiveness of XNJ in
acute IS. There is still a need for well-designed trials with large
sample sizes to further prove the effectiveness and safety of XNJ
in acute IS (Xu et al., 2005; Li, 2006; Wang et al., 2006; Lin et al.,
2010; Li et al., 2013; Ma et al., 2013; Chen and Gu, 2017; Ma et al.,
2017; Wang et al., 2017; Liao et al., 2019).
Effectiveness of Xingnaojing Injection for
Acute Ischemic Stroke
Outcomes in the included 10 SRs were classified into three
categories, including clinical outcomes related to the
effectiveness of XNJ for acute IS, surrogate outcomes, and
composite outcomes. We also classified and summarized the
different scales for each clinical outcome, and the results were
summarized as follows.
Clinical Outcomes
Outcome 1: Neurological Function
All included SRs assessed neurological function assessed by
National Institutes of Health Stroke Scale (NIHSS), Chinese
Stroke Scale (CSS), or European Stroke Scale (ESS) (Xu et al.,
2005; Li, 2006; Wang et al., 2006; Lin et al., 2010; Li et al., 2013;
Ma et al., 2013; Chen and Gu, 2017; Ma et al., 2017; Wang et al.,
2017; Liao et al., 2019), but 3 SRs pooled the data of the RCTs that
used NIHSS or CSS without subgroup analysis (Lin et al., 2010;
Ma et al., 2013; Wang et al., 2017).
Scale 1: National Institutes of Health Stroke Scale
Xingnaojing Injection + Conventional Therapy vs. Conventional
Therapy. Two SRs assessed the neurologic deficit score using the
NIHSS (Li et al., 2013; Ma et al., 2017); the results of these two SRs
showedNIHSS of patients in the XNJ group wasmuch lower. One
had no heterogeneity (Li et al., 2013) (3 RCTs, MD  −1.10, 95%
CI −1.63 to −0.56, p < 0.00001, I2  0%), while the other had high
heterogeneity (Ma et al., 2017) (12 RCTs, MD  −3.44, 95% CI
−4.52 to −2.36, p < 0.00001, I2  92%), but the researchers did not
explore potential factors for high heterogeneity.
Scale 2: Chinese Stroke Scale
Xingnaojing Injection + Conventional Therapy vs. Conventional
Therapy. Three SRs compared XNJ combined CT with CT by
CSS (Li et al., 2013; Chen and Gu, 2017; Ma et al., 2017); all results
FIGURE 1 | Flow diagram of literature selection.
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indicated the CSS in the XNJ group was much lower than that in
the control group, although two SRs with high heterogeneity
(Chen and Gu, 2017; Ma et al., 2017) (18 RCTs, MD  −5.72, 95%
CI −6.94 to −4.50, p < 0.00001, I2  87%; 5 RCTs, MD  −5.55,
95% CI −7.62 to −3.48, p < 0.00,001, I2  86%) and one SR just
included 1 RCT (WMD  −7.10, 95% CI −9.55 to −4.65) (Li et al.,
2013).
Xingnaojing Injection + Conventional Therapy vs. Other Chinese
Herbal Injections + Conventional Therapy
The results of two SRs showed XNJ can decrease the CSS
compared to Danshen injection (RCTs  6, WMD  −5.57,
95% CI −6.43 to −4.71, p < 0.00001, I2  79.3%; 3 RCTs,
WMD  3.78, 95% CI 2.30 to 5.26, p < 0.0,001) (Xu et al.,
2005; Li et al., 2013). One SR indicated XNJ can decrease the CSS
compared to Shuxuetong injection (1RCT, WMD  −1.05, 95%
CI −16.66 to −4.34, p  0.0008) and Xuesaitong injection (1 RCT,
WMD  −5, 95% CI −7.61 to −2.39, p  0.0002) (Li et al., 2013).
Xingnaojing Injection + Conventional Therapy vs. Western
Medicine + Conventional Therapy
The results of 1 SR showed that XNJ can decrease the CSS score
compared to low molecular dextran (D-40) (1 RCT, WMD 
0.63, 95% CI −0.83 to 2.09, p  0.40) (Xu et al., 2005). While 1 SR
showed a similar result, it pooled two RCTs comparing XNJ to D-
40 and Cerebrolysin, respectively (2 RCTs, WMD  −4.48,
p  0.67, 95% CI −5.19 to −3.78) (Wang et al., 2006). There
were no improvements in neurological function when compared
with Citicoline and Venoruton, respectively (1 RCT, WMD 
−2.3, p  0.34, 95% CI −2.42 to 7.02; 2 RCTs, WMD  7.05, 95%
CI −6.46 to 7.65, p < 0.00,001, I2  98.8%) (Li et al., 2013).
Scale 3: European Stroke Scale
Only 1 SR assessed the neurologic deficit score with ESS; the result
combined four different interventions in the control group
(Danshen, danhong, citicoline, and edaravone); this means
there was high heterogeneity (4 RCTs, WMD  −0.32, 95% CI
−1.39 to 0.74, p < 0.00001, I2  99.6%) (Li et al., 2013).
Outcome 2: Activity of Daily Living
The result of 1 SR indicated XNJ combined with CT could
significantly improve the ADL of acute IS patients when
compared to CT (5 RCTs, MD  10.23, 95% CI 9.47 to 10.99,
p < 0.00001, I2  0%) (Ma et al., 2017).
Outcome 3: Consciousness
Scale: Glasgow coma scale
Three SRs assessed coma with the GCS (Lin et al., 2010; Ma et al.,
2017; Liao et al., 2019), but the results were different. The results
of 2 SRs showed there were no significant differences between the
XNJ combined with CT group and the CT group (2 RCTs, MD 
1.00, 95% CI −0.96 to 2.96, p  0.32,I2  79%; 4 RCTs, SMD 
0.67, 95% CI −0.40 to 1.74, p  0.22, I2  96.5%) (Lin et al., 2010;
Ma et al., 2017), while another SR indicated that XNJ with CT was
more effective than CT by increasing the scores of GCS (4 RCTs,
MD  2.46, 95% CI 2.06 to 2.86, p < 0.0001, I2  76% (Liao et al.,
2019).
Outcome 4: Mortality
In total, 4 SRs mentioned mortality in the Methods section (Xu
et al., 2005; Wang et al., 2006; Li et al., 2013; Ma et al., 2013), but 3
SRs finally reported mortality in the Results section (Xu et al.,
2005; Wang et al., 2006; Li et al., 2013), and 1 SR pooled the data
of IS and cerebral hemorrhage (Wang et al., 2006). Two SRs
compared XNJ with Danshen injection and included the same
RCTs (Xu et al., 2005; Li et al., 2013); the results showed XNJ
might decrease the mortality (3 RCTs, RR  0.26, 95% CI 0.07 to
1.01, p  0.05, I2  0; 3 RCTs, RR  0.31, 95% CI 0.14 to 0.70, p 
0.005, I2  0). One SR also compared XNJ with Cerebrolysin, and
there were no statistical differences between the two groups (1
RCT, RR  0.92, 95% CI 0.14 to 6.27) (Xu et al., 2005).
Outcome 5: Infarct Size
One SR showed that XNJ could reduce infarction size when
compared with CT (2RCTs, MD  −1.83, 95% CI −2.49 to −1.16,
p < 0.00001, I2  78%) (Ma et al., 2017).
Surrogate Outcomes
Outcome 1: Serum Levels of Matrix Metalloproteinase-2
(MMP-2), MMP-9, and NO
One SR summarized the serum levels of MMP-2 and MMP-9
(Ma et al., 2017). Compared with the CT group, XNJ
significantly reduced the serum levels of MMP-2 and MMP-
9 (2 RCTs, MD  −11.24, 95% CI −20.83 to −1.65, p  0.02, I2 
76%; 5 RCTs, MD  −25.08, 95% CI −35.49 to −14.67, p <
0.00001, I2  66%). The results of another SR showed that XNJ
could improve the serum level of NO when compared to CT (2
RCTs, SMD  1.72, 95% CI 1.12 to 3.85, p  0.0003) (Lin et al.,
2010).
Outcome 2: Hemorheological Parameters
The results of hemorheological parameters mainly contained
whole blood viscosity (WBV), plasma viscosity (PV),
hematocrit (HCT), and fibrinogen (FIB). Two SRs indicated
that when comparing to CT, XNJ was more effective in
improving WBV (5 RCTs, MD  −1.44, 95% CI −2.18 to 0.70,
p  0.001, I2  87%; 4 RCTs, MD  −0.80, 95% CI −1.44 to −0.16,
p  0.01, I2  88%), PV (5 RCTs, MD  −0.22, 95% CI −0.37 to
−0.07, p  0.003, I2  73%; seven RCTs, MD  −0.28, 95% CI
−0.44 to −0.12, p  0.0005, I2  94%), and HCT (two SRs included
the same RCTs; 5 RCTs, MD  −3.63, 95% CI −6.23 to −1.03, p 
0.006, I2  96%) (Ma et al., 2017; Wang et al., 2017). Besides, the
result of 1 SR showed XNJ also could reduce FIB (3 RCTs, MD 
−1.14, 95% CI −1.70 to −0.57, p < 0.000 1, I2  95%) (Wang et al.,
2017).
Outcome 3: Hemodynamic Parameters and Blood Fat
The results from 1 SR indicated that compared with the CT (Ma
et al., 2017), XNJ could remarkably increase the peak-flow rate
and average velocity (2 RCTs, MD  12.66, 95% CI 10.50 to 14.81,
p < 0.00001, I2  71%; 2 RCTs, MD  9.90, 95% CI 8.63 to 11.17,
p < 0.00001, I2  81%). XNJ could significantly reduce the levels of
cholesterol and triglyceride in blood (MD  −1.06, 95% CI −1.21
to −0.92, p < 0.00001, I2  0; MD  −1.05, 95% CI −1.12 to −0.97,
p < 0.00001, I2  0).
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Outcome 4: Endothelin
Two SRs reported the pooled results of endothelin (Wang et al.,
2006; Lin et al., 2010). Compared to CT, XNJ could reduce the
level of endothelin (2 RCTs, SMD  −0.50, 95% CI −0.81 – −0.19,
p  0.001) (Lin et al., 2010). When comparing with other herbal
injections (mailuoning and Danshen), XNJ could also reduce the
level of endothelin (2 RCTs, WMD  −45.14, 95% CI −52.81 to
−37.46, p < 0.00001), but with no subgroup analysis (Wang et al.,
2006).
Composite Outcomes
Outcome: Total Effective Rate
Nine out of 10 included SRs defined total effective rate as a
primary outcome (Xu et al., 2005; Li, 2006; Wang et al., 2006; Lin
et al., 2010; Li et al., 2013; Ma et al., 2013; Chen and Gu, 2017; Ma
et al., 2017; Wang et al., 2017). The total effective rate was a
compound outcome and total effective rate  (basically cured
patients + markedly improved patients + improved patients)/
total number of patients. “Basically cured” meant CSS decreased
91–100%, “markedly improved” represented CSS decreased
46–90%, “improved” represented CSS decreased 18–45%, while
0–17% meant invalid and 0 or less meant deterioration (The
Fourth National Academic Conference on Cerebro-vascular
Diseases, 1997).
Xingnaojing Injection + Conventional Therapy vs.
Conventional Therapy
Five SRs reported that XNJ could improve total effective rate
with no heterogeneity (Lin et al., 2010; Li et al., 2013; Chen and
Gu, 2017; Ma et al., 2017; Wang et al., 2017) (38 RCTs, I2  0,
OR  3.56, 95% CI 2.94 to 4.32, p < 0.00001; 23 RCTs, I2  0, RR
 1.22, 95% CI 1.18 to 1.27, p < 0.00001; 2 RCTs, I2  0, RR 
1.30, 95% CI 1.11 to 1.53, p < 0.01; 21 RCTs, I2  0, RR  3.85,
95% CI 2.97 to 5.00, p < 0.00001; 14 RCTs, I2  0, OR  3.70,
95% CI 2.64 to 5.17, p < 0.00001), while another 2 SRs showed
the opposite result (Xu et al., 2005; Li, 2006) (1 RCT, RR  0.94,
95% CI 0.72 to 1.24; 3 RCTs, I2  0, RR  1.04, 95%CI
0.88–1.23).
Xingnaojing Injection + Conventional Therapy vs. Other
Therapy + Conventional Therapy
The results of 2 SRs showed XNJ could improve the total effective
rate (Xu et al., 2005; Li et al., 2013) when compared to Danshen (7
RCTs, I2  0, RR  1.37, 95% CI 1.26 to 1.50; 4 RCTs, I2  48.1%,
RR  1.26, 95% CI 1.12 to 1.42, p  0.0002), Citicoline (3 RCTs, I2
 0, RR  1.37, 95% CI 1.20 to 1.57, p < 0.01; 1 RCT, RR  1.30,
95% CI 1.03–1.63), and Mailuoning (1 RCT, RR  1.43, 95% CI
1.09 to 1.86, p < 0.01; 1 RCT, RR  1.36, 95% CI 1.06 to 1.75, p <
0.01). But there was no statistical difference when compared to
Cerebrolysin (the same RCT, RR  0.99, 95% CI 0.84 to 1.16, p >
0.05). One of the SRs also showed positive result when compared
to D-40 (1 RCT, RR  1.23, 95% CI 1.02, 1.47, p < 0.05) and
edaravone (1 RCT, RR  1.50, 95% CI 1.09 to 2.06, p  0.01). But
there were no statistical difference between the two groups when
compared to Hetastarch (2 RCTs, RR  0.97, 95% CI 0.80 to 1.17,
p > 0.05) and Venoruton (1 RCT, RR  1.16, 95% CI 0.97 to 1.38,
p > 0.05) (Li et al., 2013). Another SR showed positive result when
compared to Dextran-40 (1 RCT, RR  1.44, 95% CI 1.24–1.60)
(Xu et al., 2005). One SR pooled the data of all other therapies in
the control group with no subgroup analysis (Wang et al., 2006),
there was no heterogeneity (p  0.28), and the result showed XNJ
could improve total effective rate (8 RCTs, OR  2.75, 95% CI
1.90–3.99).
There was still one SR that considered the quality of included
RCT as a heterogeneity factor but with no limitations on
treatment in the control group (Ma et al., 2013). The results
of the two subgroups showed XNJ could improve the total
effective rate (JADAD  2, 2 RCTs, I2  0, RR  1.08, 95% CI
0.93 to 1.25; JADAD  1, 7 RCTs, I2  0, RR  1.36, 95% CI
1.20–1.55).
Safety of Xingnaojing Injection for Acute
Ischemic Stroke
A total of 8 SRs mentioned adverse events (Xu et al., 2005; Li,
2006; Wang et al., 2006; Lin et al., 2010; Li et al., 2013; Ma et al.,
2013; Wang et al., 2017; Liao et al., 2019), among which 3 SRs
reported that there were no adverse events in the included
original RCTs (Li, 2006; Lin et al., 2010; Ma et al., 2013) and
5 SRs reported adverse events (Xu et al., 2005; Wang et al., 2006;
Li et al., 2013; Wang et al., 2017; Liao et al., 2019). The patient
numbers of adverse events in the treatment group and the control
group were 17 VS 21 (Wang et al., 2017), 2/0 (Xu et al., 2005; Li
et al., 2013), 4/0 (Wang et al., 2006), and 8/3 (Liao et al., 2019),
respectively. The adverse events in the XNJ group included slight
skin rashes, nausea or vomiting, headache, dizziness, slight drop
in blood pressure, and gastrointestinal reactions, while the CT
group in 1 SR reported adverse events such as slight skin rashes,
nausea or vomiting, headache, dizziness, drop in blood pressure,
and gastrointestinal reactions (Wang et al., 2017). And the
symptoms were improved by slowing down the drip rate of
infusion and treating symptomatically; all the patients
completed the trials. The remaining 2 SRs did not mention
adverse events (Chen and Gu, 2017; Ma et al., 2017). The
included SRs indicated that the adverse events in the CT
group were less than that in the XNJ combined CT group, but
there was no statistical difference between the two groups.
Quality Assessment
Methodological Quality of Systematic Reviews
The results of AMSTAR 2 assessment are shown in Table 2. The
overall quality of 10 SRs (100%) were rated as critically low (Xu
et al., 2005; Li, 2006; Wang et al., 2006; Lin et al., 2010; Li et al.,
2013; Ma et al., 2013; Chen and Gu, 2017; Ma et al., 2017; Wang
et al., 2017; Liao et al., 2019), as the critical items were poorly
reported. Only 1 SR (10%) reported 50% of the 16 items (Wang
et al., 2017), while the remaining 9 SRs (90%) reported just less
than half of the items on AMSTAR 2 (Xu et al., 2005; Li, 2006;
Wang et al., 2006; Lin et al., 2010; Li et al., 2013; Ma et al., 2013;
Chen and Gu, 2017; Ma et al., 2017; Liao et al., 2019). For the
critical items, no SRs reported either predefined protocol (item
2) or comprehensive search strategy (item 4) completely. Just 1
SR (10%) provided the list of excluded studies and gave the
reasons for exclusion (item 7) (Ma et al., 2017). When it comes to
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assessment of risk of bias (RoB), 3 SRs (30%) considered random
sequence allocation and selection of the outcome report (item 9)
(Ma et al., 2017; Wang et al., 2017; Liao et al., 2019), the other 7
SRs only assessed the unconcealed allocation and blinding (Xu
et al., 2005; Li, 2006; Wang et al., 2006; Lin et al., 2010; Li et al.,
2013; Ma et al., 2013; Chen and Gu, 2017), while only 1 SR (10%)
accounted for RoB in individual studies when interpreting the
results (item 13) (Wang et al., 2017). As for statistical
combination, 6 SRs (60%) combined the result with
appropriate methods (item 11) (Xu et al., 2005; Li et al., 2013;
Ma et al., 2013; Ma et al., 2017; Wang et al., 2017; Liao et al.,
2019). The last critical item (item 15) was relevant to publication
bias, 5 SRs (50%) reported it completely (Wang et al., 2006; Lin
et al., 2010; Chen and Gu, 2017; Wang et al., 2017; Liao et al.,
2019). For the nine noncritical items, no SRs gave reasons for
including only RCTs (item 3) or reported the included SRs in
adequate detail, especially the timeframe for follow-up (item 8).
All SRs did not report or try to find the sources of funding for
individual RCTs included in the review (item 10), nor did they
assess the potential impact of RoB in individual RCTs (item 12).
The most well-reported (70%) item was the components of
patient, intervention, control group, and outcome (item 1) (Xu
et al., 2005; Wang et al., 2006; Lin et al., 2010; Li et al., 2013; Ma
et al., 2017; Wang et al., 2017; Liao et al., 2019), 6 SRs (60%)
mentioned they conducted study selection (item 5) and data
extraction (item 6) using two reviewers (Xu et al., 2005; Wang
et al., 2006; Lin et al., 2010; Ma et al., 2017; Wang et al., 2017; Liao
et al., 2019). Besides, 5 SRs (50%) explored the possible reasons
for the heterogeneity and discussed the effect on the results
caused by the heterogeneity (item 14) (Xu et al., 2005; Li
et al., 2013; Ma et al., 2017; Wang et al., 2017; Liao et al.,
2019). And 2 SRs (20%) claimed there was no conflict of
interest in the review (item 16) (Ma et al., 2013; Ma et al., 2017).
Evidence Quality of Outcomes
The important clinical outcomes were assessed except for those in
the descriptive analysis. The results of evidence quality rated by
GRADE are shown in Table 3.
There were 20 important outcomes in the 10 SRs, 7 (35%)
outcomes with low-quality evidence, 10 (50%) with very
low–quality evidence, and 3 (15%) with moderate-quality
evidence. Imprecision (100%) was the most common reason
for downgrading the quality of evidence due to the small
number of events or a wide confidence interval. Risk of bias
ranked second (85%) with 17 outcomes, except for three
outcomes of mortality in 2 SRs (Xu et al., (005)2, Li et al.,
2013), followed by inconsistency for 10 outcomes (50%). No
evidence was downgraded because of indirectness. Publication
bias was not detected.
DISCUSSION
Summary of Findings
In recent years, more and more clinical studies and SRs about the
effectiveness of XNJ in acute IS were published between 2005 and
2019. The purpose of this overview of SRs was to provide an
overall evaluation and summary of the current evidence about the
effectiveness of XNJ on acute IS. Of the 10 SRs andMAs identified
(Xu et al., 2005; Li, 2006; Wang et al., 2006; Lin et al., 2010; Li
et al., 2013; Ma et al., 2013; Chen and Gu, 2017; Ma et al., 2017;
Wang et al., 2017; Liao et al., 2019), the methodological quality
were critically low assessed by AMSTAR2, especially for the
poorly reported critical items including predefined protocol,
comprehensive search strategy, list of excluded studies, and
reasons for exclusion. Besides, the quality of included original
RCTs also influenced the quality of SRs. These 10 included SRs
indicated that XNJ were used in combination with CT in the
treatment of acute IS in most of the original RCTs. Very low– to
low-quality evidence showed that XNJ combined with CT can
improve the neurological deficits score no matter which scale is
used. And moderate-quality evidence suggested that XNJ
combined with CT could reduce mortality compared to
Danshen injection. Both the XNJ and CT groups reported
slight adverse events.
As for acute IS, no SRs reported the severity of acute IS and
only 4 SRs reported the course of disease (Li, 2006; Wang et al.,
2006; Ma et al., 2013; Wang et al., 2017). It remains unknown
whether it is more beneficial to use XNJ for acute IS as soon as
possible. A registry study (register number: NCT04275349),
considering different timepoints of XNJ as the exposure group
is being conducted to answer this question. We searched the
ongoing registered trials thoroughly for trials on XNJ for acute IS
that were registered on ClinicalTrials.gov in October 2020. Two
multicenter RCTs (XNJ as an intervention group) are currently
enrolling acute IS patients within 24 h of symptom onset, and the
sample size ranges from 720 to 1,200 patients, which indicates
that these data may be able to provide answers for some clinical
questions.
When it comes to outcomes, neurological deficits,
consciousness, and total effective rate were the frequently
used outcomes in the included SRs. Three kinds of scales
were used to assess neurological deficits, including NIHSS,
ESS, and CSS. NIHSS is more widely used with good validity
and reliability, while ESS has a high structural validity but needs
to be further verified in clinical trials (Herndon, 2006). CSS is
usually used in China, and both validity and reliability of CSS
also need further verification. Conventionally, neurological
function can only partially explain the health of the body
and cannot be used as an outcome indicator alone; the
clinical benefit of acute stroke patients is usually measured
using the modified Rankin scale (mRS) (Broderick et al.,
2017; Powers, 2020), but all the included SRs or MAs did not
measure this outcome. GCS is used to assess the degree of coma,
but it is not appropriate for stroke patients who are unconscious
(Powers, 2020). Three SRs included in this overview showed
controversial results (Lin et al., 2010; Ma et al., 2017; Liao et al.,
2019). One included unconscious stroke patients and indicated
that XNJ could improve the consciousness of patients (Liao
et al., 2019), while the other 2 SRs showed no statistical
difference and the consciousness condition of the included
patients was not clearly reported. As we have mentioned
above, the total effective rate is a compound outcome and
mainly measured using CSS when evaluating the effectiveness
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on neurological deficits. Total effective rate combine 3 levels of
CSS decrease (91–100%, 46–90% and 18–45%), and may
exaggerate the efficacy and make type I errors in statistics
(Mccoy, 2018; Yan et al., 2019; Zhang et al., 2020).
Strengths and Limitations
This overview evaluated and summarized the current evidence
about the effectiveness of XNJ on acute IS, classified the results
according to different types of outcomes, and assessed the
quality of evidence for clinical outcomes with GRADE.
Although we conducted this overview according to the
Cochrane handbook of overviews of reviews (Higgins Jpt,
2019), it still has some limitations. We focused on different
timepoints for XNJ in acute IS but could not pool the data of the
included SRs that were searched as this information in the SRs
or original RCTs was not completely reported.
Implications
Whether it is an SR or RCT to evaluate intervention effectiveness
for acute IS in the future, researchers should consider measuring
neurological deficits using a recognized and validated NIHSS and
combine the robust endpoint outcomes including mortality and
mRS. Besides, there are no specific outcomes for evaluating TCM
treatment in acute IS; studies focused on core outcome measures
for TCM treatment in acute IS have been registered on the website
of Core Outcome Measures in Effectiveness Trials (COMET),
which could provide a reference for the selection of core
outcomes for acute IS with TCM treatment in the future.
For the methodological quality of SR, future SRs should
register the protocol before commencing the study; more and
more journals also require manuscript of SRs to provide the
register protocol number. In addition, lists of excluded studies
and reasons for exclusion, publication bias and RoB, and the
influence of RoB in individual studies when present in the results
should also be reported completely.
CONCLUSION
Very low to low quality of evidence indicated XNJ combined CT
could improve the neurological deficits of acute IS, but it remains
unknown whether it is more beneficial to use XNJ for acute IS as
soon as possible after the symptom onset. Well-designed large-
scale RCTs with measurable validated endpoints are still needed
in the future studies. Slight adverse events in the CT group were
less than those in the XNJ combined CT group, and there were no
serious adverse events reported, indicating that XNJ is
relatively safe.
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ADL 5 (214/212) Seriousa Not serious Not serious Seriousc Undetected Low
GCS 2 (72/68) Seriousa Seriousb Not serious Seriousc Undetected Very low
Infarct size 2 (99/99) Seriousa Not serious Not serious Seriousc Undetected Low
Li et al. (2013) Mortality 3 (119/118) Not serious Not serious Not serious Seriousc Undetected Moderate
NIHSS 3 (212/217) Seriousa Not serious Not serious Seriousc Undetected Low
ESS 4 (217/211) Seriousa Seriousb Not serious Seriousc Undetected Very low
CSS 6 (295/274) Seriousa Seriousb Not serious Seriousc Undetected Very low
CSS 1 (48/49) Seriousa Undetected Not serious Seriousc Undetected Low
CSS 1 (32/28) Seriousa Undetected Not serious Seriousc Undetected Low
CSS 2 (63/60) Seriousa Seriousb Not serious Seriousc Undetected Very low
CSS 1 (27/26) Seriousa Undetected Not serious Seriousc Undetected Low
Lin et al. (2010) GCS 4 (236/223) Seriousa Seriousb Not serious Seriousc Undetected Very low
Xu et al. (2005) Mortality 3 (119/108) Not serious Not serious Not serious Seriousc Undetected Moderate
Mortality 1 (50/46) Not serious Undetected Not serious Seriousc Undetected Moderate
Chen and Gu,
(2017)
CSS 6 (300/294) Seriousa Seriousb Not serious Seriousc Undetected Very low
Wang et al.
(2006)
CSS 2 (168/158) Seriousa Seriousb Not serious Seriousc Undetected Very low
Liao et al. (2019) GCS 4 (268/265) Seriousa Seriousb Not serious Seriousc Undetected Very low
aHiding or blinding was not used.
bThe difference of point effect size between studies was large, confidence interval overlap between studies was little, the heterogeneity test was significant, or the I2 was large.
cSmall number of events, or confidence interval was too wide.
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APPENDIX 1
Searching Strategies on PubMed:
#1. systematic review [mesh]
#2. review [tiab]
#3. meta-analysis [mesh]
#4. systematic review [tiab]
#5. meta-analysis [tiab]
#6. meta analysis [tiab]
#7. data pooling [tiab]
#8. data poolings [tiab]
#9. Overview, Clinical Trial [tiab]
#10. Clinical Trial Overview [tiab]
#11. Xingnaojing [tiab]
#12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
#13. 11 and 12
Searching Strategies on CNKI:
SU(’中风’+’卒中’+’脑梗’+’脑栓塞’+’腔梗’+’脑血管病’+’脑缺
血’+’脑出血’) AND SU醒脑静AND SU(’系统综述’+’系统评
价’+’系统’+’Meta分析’+’荟萃分析’+’汇总分析’+’集成分
析’+’二次分析’+’衍生分析’)
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